Roger Stupp, MD
Celgene: Medical Director: Employee; Novartis: Medical Director: Employee
Celgene: Advisory Board; Novocure: Travel Expenses
Novartis: Stock Options
Medical Director, Malnati Brain Tumor Institute (Department of Neurosurgery)
Chief, Division of Neurooncology (Department of Neurology)
Associate Director for Strategic Initiatives (Lurie Cancer Center)
Northwestern Medicine, Lurie Comprehensive Cancer Center and Northwestern University Feinberg School of Medicine
Professor of Medicine (Hematology/Oncology), Neurology and Neurological Surgery
Roger Stupp trained in Internal Medicine in Switzerland and in Hematology/Oncology at the University of Chicago. He then worked over 17 years as a physician and researcher at the University of Lausanne, and from 2013 - 2017 as the Director of the Department of Oncology at the University Hospital in Zurich, Switzerland. Since April 2017 he holds an appointment as Division Chief of Neuro-Oncology and Medical Director of the Malnati Brain Tumor Institute, and as Associate Director for Strategic Initiatives of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University Feinberg School of Medicine.
Dr. Stupp has been a member of the European Organisation for Research and Treatment of Cancer (EORTC) since 1994, and serves as a member of the Board of Directors and Executive Committee since 2006 (President from 2012 – 2017). Dr. Stupp's research focuses on early drug development, the combination of chemo- and radiotherapy, multidisciplinary cancer management, namely in the areas of lung cancer and brain tumors. Roger Stupp is best known for his contributions in landmarks trials establishing temozolomide and, most recently tumor treating fields as the standard of care for glioblastoma patients.
In 2017, he took new responsibilities as leader of medical neuro-oncology and clinical brain cancer research within Northwestern University’s Robert H. Lurie Comprehensive Cancer Center and its Brain Tumor Institute. He remains dedicated to translational cancer research, scientific cooperation and believes in the importance of well-designed clinical trials conducted within academic cooperative groups.
Tuesday, October 23
1:40 PM – 2:00 PM